ARMATA PHARMACEUTICALS, INC. (ARMP) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $371.00K; Additional Paid in CapitalUSD $311.19M; Retained Earnings (Accumulated Deficit)USD $-542.74M; Stockholders' Equity Attributable to ParentUSD $-231.17M.
- 2026-03-31: Common Stock, Value, IssuedUSD $366.00K; Additional Paid in CapitalUSD $304.93M; Retained Earnings (Accumulated Deficit)USD $-616.88M; Stockholders' Equity Attributable to ParentUSD $-311.59M.
- 2025-12-31: Common Stock, Value, IssuedUSD $364.00K; Additional Paid in CapitalUSD $282.57M; Retained Earnings (Accumulated Deficit)USD $-501.53M; Stockholders' Equity Attributable to ParentUSD $-218.60M.
- 2025-09-30: Common Stock, Value, IssuedUSD $362.00K; Additional Paid in CapitalUSD $281.29M; Retained Earnings (Accumulated Deficit)USD $-377.24M; Stockholders' Equity Attributable to ParentUSD $-95.59M.
ARMATA PHARMACEUTICALS, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Preferred Stock, Value, Issued USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature USD | Adjustments to Additional Paid in Capital, Warrant Issued USD |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $371.00K | $311.19M | $-542.74M | $-231.17M | 3 month · $3.39M 6 month · $4.47M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $366.00K | $304.93M | $-616.88M | $-311.59M | 3 month · $1.07M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $364.00K | $282.57M | $-501.53M | $-218.60M | 12 month · $2.61M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $362.00K | $281.29M | $-377.24M | $-95.59M | 3 month · $622.00K 9 month · $1.98M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $362.00K | $280.70M | $-350.56M | $-69.50M | 3 month · $575.00K 6 month · $1.36M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $362.00K | $280.12M | $-334.27M | $-53.78M | 3 month · $781.00K | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $362.00K | $279.35M | $-327.74M | $-48.02M | 12 month · $2.89M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $362.00K | $279.00M | $-330.33M | $-50.97M | 3 month · $670.00K 9 month · $2.54M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $362.00K | $278.39M | $-324.85M | $-46.10M | 3 month · $1.33M 6 month · $1.87M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $361.00K | $276.97M | $-333.84M | $-56.51M | 3 month · $534.00K | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $361.00K | $276.39M | $-308.82M | $-32.06M | 12 month · $938.00K | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $361.00K | $276.23M | $-288.97M | $-12.39M | 3 month · $-373.00K 9 month · $745.00K | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $361.00K | $276.59M | $-257.81M | $19.14M | 3 month · $261.00K 6 month · $1.12M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $361.00K | $276.35M | $-254.26M | $22.45M | 3 month · $857.00K | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $361.00K | $275.49M | $-239.77M | $36.08M | 12 month · $3.10M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $361.00K | $274.68M | $-229.46M | $45.58M | 3 month · $846.00K 9 month · $2.29M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $361.00K | $273.78M | $-220.85M | $53.29M | 3 month · $949.00K 6 month · $1.44M | (m) | (m) | 3 month · $32.00K | (m) | (m) |
| 2022-03-31 | $361.00K | $272.81M | $-211.63M | $61.54M | 3 month · $493.00K | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $271.00K | $227.98M | $-202.86M | $25.40M | 12 month · $2.88M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $249.00K | $220.32M | $-196.81M | $23.75M | 3 month · $469.00K 9 month · $2.22M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $249.00K | $219.76M | $-191.39M | $28.62M | 3 month · $907.00K 6 month · $1.75M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $249.00K | $218.96M | $-185.20M | $34.01M | 3 month · $842.00K | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $187.00K | $198.37M | $-179.70M | $18.86M | 12 month · $3.48M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $187.00K | $197.51M | $-173.08M | $24.62M | 3 month · $663.00K 9 month · $2.61M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $186.00K | $196.76M | $-167.31M | $29.64M | 3 month · $906.00K 6 month · $1.95M | (m) | (m) | 3 month · $32.00K | (m) | (m) |
| 2020-03-31 | $186.00K | $195.90M | $-162.60M | $33.48M | 3 month · $1.04M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $99.00K | $172.01M | $-157.52M | $14.59M | 12 month · $4.27M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $99.00K | $170.97M | $-152.94M | $18.13M | 3 month · $2.50M 9 month · $3.22M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $99.00K | $168.51M | $-145.98M | $22.63M | 3 month · $725.00K 6 month · $725.00K | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $328.00K | $414.57M | $-409.93M | $3.96M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $51.00K | $145.69M | $-138.04M | $7.69M | 12 month · $46.00K | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $165.00K | $408.68M | $-402.00M | $8.80M | 3 month · $8.00K 9 month · $47.00K | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $165.00K | $408.56M | $-400.39M | $11.56M | 3 month · $13.00K 6 month · $39.00K | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $165.00K | $408.46M | $-397.34M | $14.71M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $95.00K | $401.84M | $-394.21M | $24.34M | 12 month · $700.00K | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $93.00K | $401.52M | $-391.85M | $9.76M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $85.00K | $400.85M | $-391.07M | $9.86M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $165.00K | $391.10M | $-384.61M | $6.65M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $16.00K | $391.07M | $-381.36M | $9.72M | 12 month · $2.00M | (m) | (m) | (m) | (m) | 12 month · $204.00K |
| 2016-09-30 | $111.00K | $389.98M | $-371.86M | $18.23M | 9 month · $1.70M | (m) | (m) | (m) | (m) | 9 month · $204.00K |
| 2016-06-30 | $111.00K | $390.86M | $-369.49M | $21.48M | 6 month · $1.36M | (m) | (m) | (m) | (m) | 6 month · $204.00K |
| 2016-03-31 | $59.00K | $374.47M | $-365.63M | $8.90M | 3 month · $816.00K | (m) | (m) | (m) | (m) | 3 month · $204.00K |
| 2015-12-31 | $59.00K | $375.18M | $-362.52M | $12.71M | 12 month · $479.00K | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | $59.00K | $375.89M | $-360.29M | $15.66M | 9 month · $249.00K | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $57.00K | $378.76M | $-365.73M | $13.09M | 6 month · $105.00K | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $2.78M | $370.64M | $-376.50M | $-3.08M | 3 month · $52.00K | (m) | (m) | (m) | (m) | 3 month · $-4.00M |
| 2015-03-16 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 1 month · $4.00M |
| 2014-12-31 | $40.00K | $365.40M | $-362.01M | $3.44M | 12 month · $775.00K | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | $1.87M | $362.00M | $-361.34M | $4.37M | 9 month · $714.00K | $87.00K | $-178.00K | (m) | (m) | (m) |
| 2014-06-30 | $1.87M | $360.92M | $-382.55M | $-17.92M | 6 month · $468.00K | $87.00K | $-85.00K | (m) | (m) | (m) |
| 2014-03-31 | $1.82M | $358.75M | $-396.42M | $-34.01M | 3 month · $234.00K | $89.00K | $-69.00K | (m) | (m) | (m) |
| 2013-12-31 | $1.82M | $358.83M | $-385.12M | $-22.62M | 12 month · $1.44M | $89.00K | $-65.00K | (m) | 12 month · $2.63M | (m) |
| 2012-12-31 | (m) | (m) | (m) | $12.94M | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |